This ensures that the control system can react quickly to the individual phases by actuating values quickly and precisely, ...
The FDA has granted a priority review to the supplemental Biologics License Application for enfortumab/pembrolizumab to all ...
Phase 3 KEYNOTE-B15 data demonstrate that perioperative enfortumab vedotin and pembrolizumab significantly improve EFS, OS, and pCR compared with standard chemotherapy.
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif. Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration ...
Priority Dispatch Corp., a provider of emergency dispatch protocol systems, has launched a SMART on FHIR application that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results